Glycosylation as a Central Integrator of Protein Function and Cellular Signaling

Glycosylation acts as a dynamic regulatory system that shapes protein function related to polygenic diseases. Beyond cancer, glycosylation plays a key regulatory role in inflammation, infectious diseases, and neurodegeneration by shaping immune recognition, host–pathogen interactions, and cellular stress responses. By modifying protein folding, stability, trafficking, and signaling, glycosylation tunes proteome behavior in a context-dependent manner and enables rapid, non-genetic cellular adaptation. Disease-associated glycosylation changes in cancer arise from reprogramming of glycosylation enzymes and are linked to oncogenic signaling, metabolic rewiring, hypoxia, and immune modulation. These regulated alterations drive disease progression and generate reproducible, tissue- and stage-specific glycan signatures. Since glycan structures encode multiple layers of cellular regulation, glycoform-resolved biomarkers can provide diagnostic sensitivity and prognostic accuracy compared to protein measurements. Advances in analytical and engineering technologies further revealed glycosylation as a therapeutically actionable layer, enabling precision strategies such as enzyme-selective inhibition, glyco-engineered antibodies, and glycan-informed immunotherapies. These insights establish glycosylation as a central integrative system connecting proteome regulation, disease mechanisms, biomarker development, and next-generation therapeutic intervention.